| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 101 | 2023 | 884 | 10.790 |
Why?
|
| Transplantation Conditioning | 41 | 2020 | 373 | 4.370 |
Why?
|
| Graft vs Host Disease | 44 | 2023 | 358 | 3.550 |
Why?
|
| Transplantation, Homologous | 76 | 2020 | 1001 | 3.260 |
Why?
|
| Hematologic Neoplasms | 24 | 2023 | 335 | 2.910 |
Why?
|
| Multiple Myeloma | 13 | 2020 | 326 | 1.760 |
Why?
|
| Lymphoma | 11 | 2017 | 264 | 1.750 |
Why?
|
| Graft vs Tumor Effect | 13 | 2015 | 25 | 1.720 |
Why?
|
| Lymphoma, Non-Hodgkin | 12 | 2012 | 262 | 1.410 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2017 | 782 | 1.320 |
Why?
|
| Lymphocyte Transfusion | 7 | 2013 | 41 | 1.260 |
Why?
|
| Transplantation, Autologous | 20 | 2020 | 340 | 1.240 |
Why?
|
| T-Lymphocytes | 17 | 2021 | 1220 | 1.220 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 11 | 2017 | 157 | 1.210 |
Why?
|
| Bone Marrow Transplantation | 17 | 2019 | 283 | 1.190 |
Why?
|
| Stem Cell Transplantation | 10 | 2020 | 188 | 1.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2019 | 2535 | 1.090 |
Why?
|
| Salvage Therapy | 4 | 2012 | 235 | 0.990 |
Why?
|
| Myelodysplastic Syndromes | 13 | 2017 | 351 | 0.970 |
Why?
|
| Immunotherapy, Adoptive | 9 | 2021 | 186 | 0.950 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2019 | 154 | 0.940 |
Why?
|
| Transplantation Chimera | 7 | 2015 | 81 | 0.920 |
Why?
|
| Lymphocyte Depletion | 7 | 2017 | 98 | 0.900 |
Why?
|
| Hodgkin Disease | 8 | 2017 | 180 | 0.810 |
Why?
|
| Humans | 138 | 2023 | 88482 | 0.790 |
Why?
|
| Adult | 81 | 2023 | 26303 | 0.780 |
Why?
|
| Blood Component Removal | 2 | 2020 | 24 | 0.770 |
Why?
|
| Graft Survival | 10 | 2016 | 912 | 0.770 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 20 | 0.750 |
Why?
|
| Leukemia | 10 | 2011 | 321 | 0.750 |
Why?
|
| Middle Aged | 75 | 2020 | 25649 | 0.740 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 10 | 2008 | 166 | 0.720 |
Why?
|
| Myeloablative Agonists | 4 | 2019 | 36 | 0.710 |
Why?
|
| Monitoring, Physiologic | 2 | 2012 | 266 | 0.700 |
Why?
|
| Female | 84 | 2021 | 45687 | 0.670 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 6 | 2015 | 64 | 0.670 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2013 | 439 | 0.630 |
Why?
|
| Male | 74 | 2019 | 41953 | 0.620 |
Why?
|
| Tissue Donors | 9 | 2020 | 497 | 0.600 |
Why?
|
| Breast Neoplasms | 9 | 2011 | 2976 | 0.580 |
Why?
|
| Treatment Outcome | 35 | 2019 | 8151 | 0.570 |
Why?
|
| Cord Blood Stem Cell Transplantation | 5 | 2019 | 89 | 0.560 |
Why?
|
| Aged | 41 | 2020 | 18904 | 0.550 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2016 | 4 | 0.550 |
Why?
|
| Lymphoma, T-Cell | 1 | 2016 | 55 | 0.520 |
Why?
|
| Hematopoietic Stem Cells | 6 | 2019 | 299 | 0.490 |
Why?
|
| Cytokines | 6 | 2021 | 801 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2020 | 1351 | 0.490 |
Why?
|
| Antigens, Neoplasm | 3 | 2012 | 330 | 0.480 |
Why?
|
| Th2 Cells | 4 | 2013 | 147 | 0.480 |
Why?
|
| Disease-Free Survival | 17 | 2019 | 1213 | 0.480 |
Why?
|
| Recurrence | 15 | 2017 | 1168 | 0.470 |
Why?
|
| Cyclophosphamide | 10 | 2023 | 300 | 0.470 |
Why?
|
| Adoptive Transfer | 2 | 2004 | 169 | 0.450 |
Why?
|
| Interleukin-7 | 2 | 2012 | 41 | 0.430 |
Why?
|
| Geriatric Assessment | 4 | 2020 | 182 | 0.420 |
Why?
|
| Immunization | 1 | 2012 | 160 | 0.410 |
Why?
|
| Education | 2 | 2011 | 57 | 0.400 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2012 | 126 | 0.370 |
Why?
|
| Etoposide | 8 | 2019 | 198 | 0.370 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2010 | 393 | 0.370 |
Why?
|
| Neoplasms | 5 | 2018 | 3003 | 0.360 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 4 | 2000 | 16 | 0.360 |
Why?
|
| Antineoplastic Agents | 11 | 2017 | 2405 | 0.360 |
Why?
|
| Thionucleotides | 4 | 2000 | 56 | 0.360 |
Why?
|
| Vincristine | 5 | 2019 | 112 | 0.350 |
Why?
|
| HLA Antigens | 6 | 2016 | 226 | 0.340 |
Why?
|
| Hematopoiesis | 5 | 2019 | 164 | 0.340 |
Why?
|
| Survival Rate | 15 | 2014 | 1881 | 0.340 |
Why?
|
| Congresses as Topic | 1 | 2010 | 112 | 0.340 |
Why?
|
| Adolescent | 25 | 2016 | 9141 | 0.340 |
Why?
|
| Doxorubicin | 5 | 2019 | 298 | 0.320 |
Why?
|
| Remission Induction | 11 | 2017 | 734 | 0.320 |
Why?
|
| Survival Analysis | 15 | 2017 | 1542 | 0.320 |
Why?
|
| National Cancer Institute (U.S.) | 7 | 2013 | 73 | 0.320 |
Why?
|
| Oligonucleotides, Antisense | 3 | 1997 | 68 | 0.310 |
Why?
|
| Neoplasm, Residual | 5 | 2013 | 176 | 0.310 |
Why?
|
| Prednisone | 4 | 2019 | 258 | 0.310 |
Why?
|
| Vidarabine | 5 | 2019 | 143 | 0.300 |
Why?
|
| Rituximab | 3 | 2019 | 119 | 0.280 |
Why?
|
| Graft Rejection | 5 | 2016 | 1083 | 0.280 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2013 | 11 | 0.280 |
Why?
|
| Secondary Prevention | 7 | 2013 | 163 | 0.280 |
Why?
|
| Lymphoma, B-Cell | 2 | 2020 | 105 | 0.270 |
Why?
|
| Interleukin-4 | 1 | 2006 | 130 | 0.270 |
Why?
|
| Immunosuppressive Agents | 6 | 2019 | 994 | 0.270 |
Why?
|
| Severity of Illness Index | 3 | 2010 | 1842 | 0.270 |
Why?
|
| Young Adult | 14 | 2021 | 6193 | 0.250 |
Why?
|
| Combined Modality Therapy | 13 | 2012 | 1709 | 0.250 |
Why?
|
| Prospective Studies | 10 | 2020 | 4268 | 0.240 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2010 | 173 | 0.240 |
Why?
|
| Registries | 2 | 2007 | 754 | 0.230 |
Why?
|
| Sirolimus | 3 | 2015 | 173 | 0.220 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 50 | 0.220 |
Why?
|
| Child, Preschool | 8 | 2016 | 3671 | 0.210 |
Why?
|
| Histocompatibility Testing | 5 | 2017 | 138 | 0.210 |
Why?
|
| Transplantation Immunology | 4 | 2013 | 82 | 0.210 |
Why?
|
| Whole-Body Irradiation | 5 | 2019 | 66 | 0.210 |
Why?
|
| Fetal Blood | 3 | 2017 | 90 | 0.210 |
Why?
|
| Retrospective Studies | 18 | 2019 | 8869 | 0.210 |
Why?
|
| Bone Marrow Purging | 3 | 2002 | 7 | 0.200 |
Why?
|
| Time Factors | 8 | 2013 | 5309 | 0.200 |
Why?
|
| Flow Cytometry | 4 | 2012 | 691 | 0.190 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 20 | 0.190 |
Why?
|
| Child | 11 | 2016 | 7081 | 0.190 |
Why?
|
| Leukocyte Transfusion | 1 | 2000 | 15 | 0.180 |
Why?
|
| Immunophenotyping | 4 | 2016 | 217 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 3 | 2017 | 1401 | 0.180 |
Why?
|
| Haplotypes | 3 | 2019 | 637 | 0.180 |
Why?
|
| Clinical Trials as Topic | 6 | 2011 | 1142 | 0.180 |
Why?
|
| United States | 11 | 2020 | 6877 | 0.180 |
Why?
|
| Glucocorticoids | 2 | 2015 | 358 | 0.180 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 46 | 0.170 |
Why?
|
| Interleukin-15 | 2 | 2012 | 73 | 0.170 |
Why?
|
| Unrelated Donors | 2 | 2017 | 44 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 863 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 130 | 0.160 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 60 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 126 | 0.160 |
Why?
|
| Quality of Life | 3 | 2013 | 1647 | 0.150 |
Why?
|
| Killer Cells, Natural | 5 | 2011 | 274 | 0.150 |
Why?
|
| CD3 Complex | 2 | 2008 | 134 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 1704 | 0.150 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 289 | 0.150 |
Why?
|
| Chronic Disease | 8 | 2012 | 948 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 196 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 2 | 2011 | 155 | 0.150 |
Why?
|
| Antigens, CD34 | 4 | 2017 | 158 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 328 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2019 | 398 | 0.150 |
Why?
|
| Power Plants | 1 | 1997 | 5 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2019 | 283 | 0.150 |
Why?
|
| Radioactive Hazard Release | 1 | 1997 | 8 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 302 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2008 | 66 | 0.140 |
Why?
|
| Prognosis | 8 | 2018 | 3749 | 0.140 |
Why?
|
| Survivors | 3 | 2013 | 233 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 1999 | 258 | 0.140 |
Why?
|
| Acute Disease | 4 | 2013 | 838 | 0.140 |
Why?
|
| Haploidy | 1 | 2016 | 32 | 0.140 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 10 | 0.140 |
Why?
|
| Neoplasm Metastasis | 4 | 2015 | 1095 | 0.130 |
Why?
|
| Anthracyclines | 1 | 2016 | 38 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2011 | 111 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 388 | 0.130 |
Why?
|
| Blood Donors | 1 | 2015 | 24 | 0.130 |
Why?
|
| Lymphocytes | 1 | 1998 | 470 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 1997 | 160 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 168 | 0.130 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 64 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 661 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 77 | 0.130 |
Why?
|
| Preoperative Period | 2 | 2018 | 94 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 107 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 100 | 0.120 |
Why?
|
| Donor Selection | 1 | 2015 | 74 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 318 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 303 | 0.120 |
Why?
|
| Medical Oncology | 2 | 2009 | 375 | 0.120 |
Why?
|
| Pilot Projects | 4 | 2020 | 865 | 0.120 |
Why?
|
| Cause of Death | 3 | 2018 | 270 | 0.120 |
Why?
|
| Comorbidity | 3 | 2018 | 947 | 0.120 |
Why?
|
| Risk Factors | 8 | 2018 | 5439 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 760 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 283 | 0.110 |
Why?
|
| Consensus | 1 | 2015 | 352 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2006 | 317 | 0.110 |
Why?
|
| Antigens, CD19 | 1 | 2013 | 41 | 0.110 |
Why?
|
| Disease Progression | 5 | 2016 | 1489 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2013 | 56 | 0.110 |
Why?
|
| Transplantation, Haploidentical | 3 | 2017 | 27 | 0.110 |
Why?
|
| Cohort Studies | 8 | 2014 | 2833 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2000 | 112 | 0.110 |
Why?
|
| Neutrophils | 3 | 2019 | 308 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1239 | 0.110 |
Why?
|
| Hemocyanins | 1 | 2012 | 7 | 0.110 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2012 | 12 | 0.110 |
Why?
|
| Health Status | 2 | 2013 | 368 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2007 | 587 | 0.110 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2012 | 6 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2016 | 427 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2013 | 232 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2013 | 165 | 0.100 |
Why?
|
| Recombinant Proteins | 4 | 2008 | 1020 | 0.100 |
Why?
|
| Chimerism | 3 | 2020 | 37 | 0.100 |
Why?
|
| Epitopes | 1 | 2012 | 255 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 2019 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 178 | 0.100 |
Why?
|
| Infant | 4 | 2013 | 3113 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2012 | 108 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2019 | 290 | 0.090 |
Why?
|
| Sickness Impact Profile | 2 | 2011 | 27 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 282 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2011 | 55 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 697 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2013 | 321 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2012 | 181 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 1 | 2011 | 119 | 0.090 |
Why?
|
| Filgrastim | 2 | 2000 | 57 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 162 | 0.090 |
Why?
|
| Group Processes | 1 | 2010 | 31 | 0.090 |
Why?
|
| B-Lymphocytes | 3 | 2011 | 736 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2008 | 2285 | 0.090 |
Why?
|
| Prednisolone | 2 | 2012 | 40 | 0.090 |
Why?
|
| Sarcoma | 1 | 2011 | 220 | 0.090 |
Why?
|
| Peptide Library | 1 | 2009 | 84 | 0.080 |
Why?
|
| Tumor Lysis Syndrome | 2 | 2013 | 9 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 902 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1038 | 0.080 |
Why?
|
| Thiazoles | 1 | 2010 | 128 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2006 | 1982 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2008 | 729 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2010 | 306 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2013 | 394 | 0.080 |
Why?
|
| Animals | 7 | 2009 | 27203 | 0.080 |
Why?
|
| CD8 Antigens | 1 | 2008 | 82 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6713 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2009 | 858 | 0.080 |
Why?
|
| Living Donors | 2 | 2008 | 344 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2008 | 50 | 0.080 |
Why?
|
| Siblings | 1 | 2008 | 111 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 132 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2009 | 143 | 0.080 |
Why?
|
| Leukocyte Count | 2 | 2016 | 222 | 0.080 |
Why?
|
| Vulvovaginitis | 1 | 2007 | 3 | 0.080 |
Why?
|
| Lymphocytosis | 1 | 2007 | 11 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 3653 | 0.080 |
Why?
|
| Biomarkers | 2 | 2019 | 1757 | 0.080 |
Why?
|
| Bioethical Issues | 1 | 2007 | 38 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 2008 | 135 | 0.070 |
Why?
|
| Lymphocyte Count | 1 | 2007 | 98 | 0.070 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2007 | 5 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2010 | 372 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1427 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2001 | 409 | 0.070 |
Why?
|
| Estrogens | 1 | 2007 | 201 | 0.070 |
Why?
|
| Histocompatibility | 3 | 2016 | 66 | 0.070 |
Why?
|
| Stem Cells | 1 | 2009 | 369 | 0.070 |
Why?
|
| PUVA Therapy | 1 | 2006 | 24 | 0.070 |
Why?
|
| Saliva | 1 | 2007 | 123 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 960 | 0.070 |
Why?
|
| Proteome | 1 | 2007 | 131 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 603 | 0.060 |
Why?
|
| Melphalan | 2 | 2019 | 98 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2009 | 510 | 0.060 |
Why?
|
| Immunologic Memory | 1 | 2006 | 161 | 0.060 |
Why?
|
| Conjunctivitis | 1 | 2004 | 6 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 575 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2004 | 71 | 0.060 |
Why?
|
| Risk | 2 | 2011 | 660 | 0.060 |
Why?
|
| Incidence | 5 | 2015 | 1588 | 0.060 |
Why?
|
| Cicatrix | 1 | 2004 | 66 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 160 | 0.060 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2004 | 37 | 0.060 |
Why?
|
| Inflammation | 1 | 2009 | 961 | 0.060 |
Why?
|
| Allografts | 2 | 2015 | 177 | 0.060 |
Why?
|
| Urate Oxidase | 1 | 2003 | 11 | 0.060 |
Why?
|
| Placebos | 2 | 2000 | 213 | 0.060 |
Why?
|
| Vaccination | 1 | 2005 | 269 | 0.060 |
Why?
|
| Models, Animal | 1 | 2004 | 276 | 0.050 |
Why?
|
| Hyperuricemia | 1 | 2003 | 24 | 0.050 |
Why?
|
| Australia | 1 | 2023 | 100 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2003 | 70 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 217 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 266 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2003 | 1712 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2003 | 213 | 0.050 |
Why?
|
| Idarubicin | 1 | 2001 | 8 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1764 | 0.050 |
Why?
|
| Cell Survival | 2 | 2001 | 980 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2002 | 295 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2001 | 127 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2001 | 109 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 116 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2010 | 1520 | 0.050 |
Why?
|
| Cytogenetic Analysis | 1 | 2000 | 71 | 0.050 |
Why?
|
| Platelet Count | 1 | 2000 | 93 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2003 | 465 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 699 | 0.050 |
Why?
|
| Iron Chelating Agents | 1 | 2000 | 4 | 0.040 |
Why?
|
| Cell Movement | 1 | 2004 | 783 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2006 | 2441 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 50 | 0.040 |
Why?
|
| Lymphoma, Follicular | 2 | 1998 | 73 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 248 | 0.040 |
Why?
|
| Patient Selection | 2 | 2019 | 689 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 83 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 64 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2000 | 478 | 0.040 |
Why?
|
| Iron | 1 | 2000 | 166 | 0.040 |
Why?
|
| Aspergillus | 1 | 1998 | 9 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2019 | 88 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 1860 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2019 | 75 | 0.040 |
Why?
|
| Gastroparesis | 1 | 1998 | 14 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 79 | 0.040 |
Why?
|
| Aspergillosis | 1 | 1998 | 41 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2011 | 123 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 272 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2019 | 266 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2019 | 374 | 0.040 |
Why?
|
| Premedication | 1 | 2017 | 57 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 264 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 274 | 0.040 |
Why?
|
| Nausea | 1 | 1998 | 176 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 379 | 0.040 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1997 | 11 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2015 | 275 | 0.040 |
Why?
|
| Ukraine | 1 | 1997 | 17 | 0.040 |
Why?
|
| Vomiting | 1 | 1998 | 193 | 0.040 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 1996 | 7 | 0.040 |
Why?
|
| Blast Crisis | 1 | 1996 | 36 | 0.040 |
Why?
|
| Parkinson Disease, Secondary | 1 | 1996 | 4 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 771 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1129 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 645 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 34 | 0.030 |
Why?
|
| Pentostatin | 1 | 2015 | 30 | 0.030 |
Why?
|
| Rabbits | 1 | 1996 | 640 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 24 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2021 | 660 | 0.030 |
Why?
|
| Methotrexate | 1 | 1995 | 250 | 0.030 |
Why?
|
| Mice | 3 | 2004 | 11700 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 150 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 927 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 139 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1248 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3029 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 84 | 0.030 |
Why?
|
| Mental Health | 1 | 2013 | 174 | 0.030 |
Why?
|
| Cell Division | 3 | 2001 | 696 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2012 | 44 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 2001 | 1056 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 565 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 374 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2011 | 47 | 0.020 |
Why?
|
| Hematology | 1 | 2011 | 30 | 0.020 |
Why?
|
| Mitogens | 2 | 2003 | 63 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 432 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 1256 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 304 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2010 | 74 | 0.020 |
Why?
|
| Bone Marrow | 2 | 2007 | 444 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2011 | 265 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1048 | 0.020 |
Why?
|
| Dasatinib | 1 | 2010 | 37 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 994 | 0.020 |
Why?
|
| Sclerosis | 1 | 2010 | 29 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2010 | 73 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 333 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 289 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 328 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 84 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 170 | 0.020 |
Why?
|
| Data Mining | 1 | 2009 | 42 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2009 | 82 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 2434 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2010 | 215 | 0.020 |
Why?
|
| Leukapheresis | 1 | 2008 | 19 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2008 | 79 | 0.020 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2008 | 2 | 0.020 |
Why?
|
| CD56 Antigen | 1 | 2008 | 18 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2008 | 20 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 160 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2008 | 30 | 0.020 |
Why?
|
| Contraindications | 1 | 2007 | 71 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2007 | 96 | 0.020 |
Why?
|
| Primary Myelofibrosis | 1 | 2008 | 57 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 891 | 0.020 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2007 | 5 | 0.020 |
Why?
|
| Lactoferrin | 1 | 2007 | 11 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 27 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 2007 | 24 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 2007 | 91 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2007 | 75 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2007 | 82 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2007 | 105 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2006 | 18 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 612 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 476 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2000 | 430 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 502 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2062 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2010 | 389 | 0.020 |
Why?
|
| Bone Marrow Cells | 2 | 1998 | 259 | 0.020 |
Why?
|
| Antimetabolites | 1 | 2003 | 24 | 0.010 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 2003 | 27 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 192 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 2590 | 0.010 |
Why?
|
| Allopurinol | 1 | 2003 | 78 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2874 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 198 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2003 | 148 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 48 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 580 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 151 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 305 | 0.010 |
Why?
|
| Biological Transport | 1 | 2001 | 399 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 543 | 0.010 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2000 | 12 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 2000 | 22 | 0.010 |
Why?
|
| Cadmium | 1 | 2000 | 28 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2000 | 120 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2000 | 172 | 0.010 |
Why?
|
| Neutropenia | 1 | 2000 | 216 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2003 | 745 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2000 | 69 | 0.010 |
Why?
|
| Copper | 1 | 2000 | 75 | 0.010 |
Why?
|
| Zinc | 1 | 2000 | 93 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1513 | 0.010 |
Why?
|
| Erythromycin | 1 | 1998 | 10 | 0.010 |
Why?
|
| Gastric Emptying | 1 | 1998 | 25 | 0.010 |
Why?
|
| Toxicity Tests | 1 | 1998 | 13 | 0.010 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 1998 | 8 | 0.010 |
Why?
|
| K562 Cells | 1 | 1998 | 44 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1998 | 91 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 1528 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1998 | 147 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 1998 | 172 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2000 | 299 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1998 | 261 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1998 | 397 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1998 | 166 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 205 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 453 | 0.010 |
Why?
|
| Gastrointestinal Agents | 1 | 1998 | 166 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2000 | 837 | 0.010 |
Why?
|
| Haloperidol | 1 | 1996 | 30 | 0.010 |
Why?
|
| Levodopa | 1 | 1996 | 36 | 0.010 |
Why?
|
| Carmustine | 1 | 1996 | 70 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1944 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1996 | 138 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1996 | 277 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2000 | 2008 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1994 | 471 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1993 | 40 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1994 | 1848 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 2331 | 0.010 |
Why?
|